Physician profile
Sanjay Raina
NPI 1669530028
$9,042.39
in general payments reported to CMS, 2019-2025
42 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $946 · 2021: $1,496 · 2022: $1,004 · 2023: $1,172 · 2024: $1,570 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,141 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.79 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,319.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $939.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $900.06 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $874.58 | 2019-2025 | |
| Pfizer INC. | $612.67 | 2019-2025 | |
| Amgen INC. | $567.23 | 2019-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $501.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.24 | 2019-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $329.91 | 2019-2025 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $318.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $298.72 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $244.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $234.44 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $204.46 | 2019-2025 | Rexulti |
| Amarin Pharma, INC. | $160.47 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.